Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid - Wikidata - awgldk - TriplyDB

Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid

Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid

http://www.wikidata.org/entity/Q35762247

about

Immunotherapy as treatment for Alzheimer’s disease Tailoring the antibody response to aggregated Aß using novel Alzheimer-vaccines Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer's disease model.Successful adjuvant-free vaccination of BALB/c mice with mutated amyloid beta peptides.Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy.NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade.Oligomeric tau-targeted immunotherapy in Tg4510 mice.Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds.Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy Amyloid β and Tau Alzheimer's disease related pathology is reduced by Toll-like receptor 9 stimulation.Current and future treatments for Alzheimer's disease Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology Blocking the apolipoprotein E/amyloid-β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice.Improvement of memory deficits and amyloid-β clearance in aged APP23 mice treated with a combination of anti-amyloid-β antibody and LXR agonist Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.Ocular manifestations of Alzheimer's disease in animal models.Microglia in Alzheimer's Disease: It's All About Context.Continuous vaccinations of 4Aβ1-15 induces specific fluctuation of inflammatory factors accompany with pathologic alterations alleviation in APP/PS1 mice.Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial Therapeutic approaches for prion and Alzheimer's diseases.Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker?Current and future therapy in Alzheimer's disease.Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy.Amyloid-beta immunisation for Alzheimer's disease Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions.Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial.Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice.Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations.Alternative Abeta immunotherapy approaches for Alzheimer's disease.Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease.Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.Vaccination as a therapeutic approach to Alzheimer's disease.Murine models of Alzheimer's disease and their use in developing immunotherapies.Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.

P2860

Q22241491-97EE5997-685E-4E82-B3BA-8A749BF7F611 Q27320084-0DAF597A-48B3-4AF4-A78D-A91CAD2237AB Q28488690-CC133955-DD51-41DE-A52B-3EFAFAB6AB8E Q30499456-3A540FAB-B41B-4F13-B83F-15AED0A2D00D Q30581976-566D1FE7-D832-4C54-946E-951E7B52CCCE Q33320228-70DADD7D-7E5F-4AC2-8F14-EF012B82E911 Q33332164-6217774E-267E-4C17-9713-8E3DE0CF9AA7 Q33496256-EBA0D67E-4429-4ADB-B317-EECF8C96C94F Q33846761-E0F7BC17-F814-4885-B243-8AD49122776C Q33935251-334E3AAC-02D9-49C1-9002-E4EC450C44C4 Q33969633-BBF6C5E9-3473-4D5E-A4A6-CC2202B5FBFF Q34219814-E413F38B-1A03-4229-A761-873F9BF42D02 Q34227162-59720862-1063-4A93-8386-9E507A62189B Q34646921-E55E660D-463B-4EB6-8D3F-6E68C4334D98 Q34943311-F2446C30-64BC-406F-A7A2-CE293365BA61 Q35095392-D43C9050-5FE6-46B1-A4D2-A7A22E635B04 Q35137114-1819F8B7-3489-4377-ADD3-0D712CBB95E7 Q35156471-2EAA1B17-6E29-41AD-9A93-0D5A958A9AC6 Q35993835-E98C25C8-D70B-46F9-A8D3-92345BE71B4B Q36072124-41B0D79B-2083-4F64-A607-3E141658BD4A Q36388994-660BB193-DD92-4106-9717-32EC9A213E54 Q36558485-665E1793-3420-4167-84D0-59C6412E6F65 Q36631376-9A31D87C-B43E-434C-9546-124A3750C5BA Q36790089-D0142B5A-AA23-4841-9730-DA873C490FB4 Q36872884-D3C69EEB-5FF9-43F2-8F03-30E3B4FC19AD Q37118083-B9E8AB9E-5921-42B2-845A-D041715856D6 Q37165703-152546AB-4A1A-4208-B67E-923FF09E49C2 Q37215851-F2DC128D-5982-4BD0-8042-373062DEE355 Q37230661-15B2E1A7-2D46-4572-85EB-FC21A54E541B Q37247201-9658EE3D-053A-4149-9C2D-ED60F912141F Q37342565-19942FF7-E942-4944-839E-650F9D85A426 Q37411415-8E89B9C5-C66D-452A-974C-3ADF8943ECF0 Q37435248-155247E7-F858-4B3D-AC55-03883462FA9B Q37438255-1389E4FB-D543-4A91-83AA-817E641494A5 Q37438261-F006F038-1681-482A-B2A1-9475C3BAA327 Q37546119-3F2E3D21-E5F6-40BF-B53D-19357F04B351 Q37655247-F183B31E-6A98-44BE-A8DA-6F0899772EEE Q37681432-892C31CC-BB97-4FAD-9E20-A5B6237D578E Q37752915-146B559C-C27F-4D53-A65C-09A28A86FF30 Q37810956-14470807-9396-4F5F-9282-BD599EC8563A

P2860

Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid

http://www.wikidata.org/entity/Q35762247

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Amyloid-beta vaccination, but ...... oth reduce parenchymal amyloid

@ast

Amyloid-beta vaccination, but ...... oth reduce parenchymal amyloid

@en

type

label

Amyloid-beta vaccination, but ...... oth reduce parenchymal amyloid

@ast

Amyloid-beta vaccination, but ...... oth reduce parenchymal amyloid

@en

prefLabel

Amyloid-beta vaccination, but ...... oth reduce parenchymal amyloid

@ast

Amyloid-beta vaccination, but ...... oth reduce parenchymal amyloid

@en

P1433

Q35762247-99DDE442-CFD9-46CE-928B-0AAF85EB3147

P1476

Q35762247-465152E1-2FA7-4CF7-85E0-525924074ED0

P2093

Q35762247-0630C38A-74C4-4C4F-A75E-BEE4BAAE6A9C

Q35762247-350A1A62-1D32-4D3D-81CC-A120AA77FE41

Q35762247-8D8BD5D1-0C7B-4B1E-A2E6-26A3BC8F436C

Q35762247-A0C22D49-442E-474C-9F67-F0CCF2115414

Q35762247-A758A861-9A49-4E40-8E11-FA9A215B9412

P2860

Q35762247-008E87FF-63AA-46EF-827F-12DFA2E673D6

Q35762247-07C6EA00-1E9A-46A5-AEE5-3C36ACD89191

Q35762247-07DC441F-83BC-407A-9BAF-FC9D3D7B3988

Q35762247-173988EA-CE9F-431A-AFEC-B4F32675BBA2

Q35762247-3318E147-6882-498C-8FE9-ADACC1CB3E80

Q35762247-40F61A94-BD71-4ACA-A16A-B5D8A3A460D6

Q35762247-475ED5BA-3302-4CA7-9883-FA156E66738E

Q35762247-5C16E77A-0434-436C-BED6-E7D0AAE856DD

Q35762247-5CAA85C2-10EF-40BC-B2DB-285AEA58D411

Q35762247-5F759DC2-F2B2-4483-B7B4-4A859AF3EA02

P304

Q35762247-E52C6E00-351D-4F3A-AB81-3CBA14228289

P31

Q35762247-EDFF80D4-696C-4BB1-AE66-68D185C43A88

P356

Q35762247-511D0534-2B99-49D7-9897-4525725593FD

P407

Q35762247-2C91C133-6690-4210-883A-7973BE3FF8E3

P433

Q35762247-5F20598A-D978-45FC-97B1-E0840D8F2122

P478

Q35762247-40003E7B-3211-4AAB-AA54-66DB318BD146

P577

Q35762247-3E3AEF52-5860-44C3-83E2-82C3341F9859

P5875

Q35762247-4E7C9BAC-A0E4-4E79-BE28-8306628D25A8

P698

Q35762247-D140F654-6E5F-4021-B4F1-AF6A9DDA039E

P932

Q35762247-7CF8394F-B257-4089-95C6-80907FE20111

P356

J.NEUROSCIENCE.2006.10.020

P1433

P1476

Amyloid-beta vaccination, but ...... oth reduce parenchymal amyloid

@en

P2093

D M Wilcock

http://www.w3.org/2001/XMLSchema#string

D Morgan

http://www.w3.org/2001/XMLSchema#string

M N Gordon

http://www.w3.org/2001/XMLSchema#string

P T Jantzen

http://www.w3.org/2001/XMLSchema#string

Q Li

http://www.w3.org/2001/XMLSchema#string

P2860

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse

Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage

Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1

Inflammation and Alzheimer's disease

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review.

P304

950-960

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEUROSCIENCE.2006.10.020

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

144

http://www.w3.org/2001/XMLSchema#string

P577

2006-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6660635

http://www.w3.org/2001/XMLSchema#string

P698

17137722

http://www.w3.org/2001/XMLSchema#string

P932

1857306

http://www.w3.org/2001/XMLSchema#string